Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Femasys Inc (NQ: FEMY )

1.060 -0.030 (-2.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 63,780
Open 1.090
Bid (Size) 1.050 (98)
Ask (Size) 1.100 (6)
Prev. Close 1.090
Today's Range 1.050 - 1.090
52wk Range 0.2479 - 4.750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Femasys Inc. at August 20th Virtual Investor Summit Microcap Event
Via ACCESSWIRE
FEMY Stock Earnings: Femasys Misses EPS, Misses Revenue for Q2 2024
FEMY stock results show that Femasys missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
+4.95%
+4.95%
1 Month
-5.36%
-5.36%
3 Month
-15.87%
-15.87%
6 Month
-13.82%
-13.82%
1 Year
+135.61%
+135.61%

More News

Read More
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
From Femasys Inc.
Via GlobeNewswire
Deep Dive Into Femasys Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Gold Rises 1%; Accenture Shares Surge After Q3 Results
Via Benzinga
Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe
From Femasys Inc.
Via GlobeNewswire
EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says
Via Benzinga
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
From Femasys Inc.
Via GlobeNewswire
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council
From Femasys Inc.
Via GlobeNewswire
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
From Femasys Inc.
Via GlobeNewswire
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
From Femasys Inc.
Via GlobeNewswire
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
From Femasys Inc.
Via GlobeNewswire
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
From Femasys Inc.
Via GlobeNewswire
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
From Femasys Inc.
Via GlobeNewswire
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
From Femasys Inc.
Via GlobeNewswire
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.